Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, have improved survival of patients with multiple myeloma (MM). However, these therapies are associated with an increased risk of venous thromboembolism (VTE). Apixaban has been approved for treatment of acute VTE...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Robert Frank Cornell, Samuel Z. Goldhaber, Brian G. Engelhardt, Javid Moslehi, Madan Jagasia, Daryl Patton, Shelton Harrell, Robert Hall, Houston Wyatt, Greg Piazza
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2019-02-01
Colecção:	Frontiers in Oncology
Assuntos:	Apixaban (Eliquis®) myeloma anticoagulation (AC) immunomodualtors venous thomboembolism
Acesso em linha:	https://www.frontiersin.org/article/10.3389/fonc.2019.00045/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!